KRYS Krystal Biotech Inc

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2024 financial results on Monday, May 6, 2024, prior to the open of U.S. markets.

The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, May 6, 2024, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: .

For those unable to listen to the live webcast, a replay will be available for 30 days on the Investors section of the Company’s website at .

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit , and follow @KrystalBiotech on and (formerly Twitter).

CONTACT

Investors and Media:                                                             

Stéphane Paquette, PhD

Krystal Biotech



EN
26/04/2024

Underlying

KRYSKrystal Biotech Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Krystal Biotech Inc

 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Announces First Quarter 2024 Financial Results and Pro...

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates Net product revenue of $45.3 million in 1Q and $95.9 million since AugustFirst patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lungReceived Fast Track Designations for both inhaled and intratumoral KB707Strong balance sheet with $622.3 million in cash and investments PITTSBURGH, May 06, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the first qua...

8h / 25m 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Present at the Association for Research in Vision a...

Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data highlighting the potential of the Company’s HSV-1 based vector platform for back of the eye gene delivery at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held from May 5-9, 2024 in Seattle, Washington. Poster presentation details are as follows: Ti...

May 2, 2024 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Report First Quarter 2024 Financial Results on May ...

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2024 financial results on Monday, May 6, 2024, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, May 6, 2024, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: . For those unable ...

April 26, 2024 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Tria...

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung • Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the first patient was dosed in its Phase 1 clinical trial (KYANITE-1) evaluating inhaled KB707, a modified HSV-1 vector designed to deliver genes encoding both human interleukin-12 (IL-12) and interleukin-2 (IL...

April 22, 2024 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Present at the American Association for Cancer Rese...

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanced local and systemic effector T-cell responses in cold tumor preclinical model PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data on local and systemic immune activation following intratumoral injection of the Company’s platform technology encoding murine interleukin-12 (IL-12) and interleuki...

April 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch